Earnings ·
Reports Q3 net loss of $1.7M; cash position stands at $13.8 million
CALCCalciMedica, Inc.
CalciMedica reported a net loss of $1.7 million for the third quarter ended September 30, 2026, or $0.24 per share, compared to a net loss of $7.8 million in the prior-year period. The improvement was driven by a $3.1 million non-cash gain from changes in the fair value of financial instruments. Research and development expenses decreased to $2.3 million from $3.9 million as clinical trial activities slowed, while general and administrative costs rose slightly to $2.4 million. The company held $13.8 million in cash, cash equivalents, and short-term investments, which management expects will fund operations into the second half of 2027. CalciMedica is a clinical-stage biopharmaceutical company developing calcium release-activated calcium channel inhibition therapies for inflammatory and cardiopulmonary diseases.